AI Digital Twin Startup Simile Raises $100M
Simile, a startup developing AI-powered digital twins of complex biological processes, has secured $100 million in a new funding round. The investment reflects growing confidence in using virtual models for process optimization and scale-up in regulated biomanufacturing. In a related development, a top-five global life sciences manufacturer has selected the On Time Edge platform for an enterprise-scale digital twin implementation, signaling a move from pilot projects to broader adoption.
- The cell and gene therapy CDMO market is projected to grow at a compound annual growth rate (CAGR) of approximately 27-28% between 2025 and 2034, driven by a robust therapy pipeline and increased venture capital funding. North America held the largest market share in 2024, accounting for over 40% of the market. - Digital twins in biopharma can be applied at the component, asset, system, or process level to simulate, monitor, and optimize operations like cell culture and fermentation. Companies like GlaxoSmithKline have used the technology to refine vaccine adjuvant production, while Merck is collaborating with Unlearn.AI to use digital twins in clinical trials. - Key challenges in viral vector manufacturing for gene therapies include low yields, production complexities, and scalability issues moving from adherent to suspension cell culture systems. A significant bottleneck is the high dosage often required for AAV-based therapies, which intensifies the need for efficient, large-scale production methods. - The biotech funding environment in 2025 was characterized by market volatility, creating a "have and have nots" dynamic where companies with strong clinical data thrived while others struggled. In early 2026, venture capital continues to flow to companies with platform technologies and those in Phase I or II studies, with notable investments in firms like ILiAD Biotechnologies ($115M) and Angitia Biopharmaceuticals ($130M). - Implementing Industry 4.0 and digital systems in GMP environments requires a strong focus on data integrity to comply with regulations like 21 CFR Part 11. This involves validating electronic systems, ensuring ALCOA+ (attributable, legible, contemporaneous, original, accurate) principles are met, and establishing robust data governance to prevent lapses that could lead to regulatory action. - The competitive landscape for bioprocess simulation and digital twin technology includes major players like Siemens, Dassault Systèmes, and Certara, alongside more specialized firms such as Aizon and Insilico Medicine. These companies offer solutions ranging from no-code simulation software to fully integrated AI-orchestrated bioprocessing platforms.
